BiotechTube

Raltegravir + Placebo + Current ART

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV

Conditions

HIV

Trial Timeline

Jul 28, 2017 → Apr 30, 2020

NCT ID
NCT03029689

About Raltegravir + Placebo + Current ART

Raltegravir + Placebo + Current ART is a phase 3 stage product being developed by Merck for HIV. The current trial status is completed. This product is registered under clinical trial identifier NCT03029689. Target conditions include HIV.

What happened to similar drugs?

20 of 20 similar drugs in HIV were approved

Approved (20) Terminated (1) Active (0)
✅Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVCiplaApproved
✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
✅Lopinavir/RitonavirAbbVieApproved
✅Ritonavir boosted Atazanavir + Raltegravir + TDF/FTC (or 3TC)MerckApproved
✅RaltegravirMerckApproved
✅raltegravirMerckApproved
✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03029689Phase 3Completed

Competing Products

20 competing products in HIV

See all competitors
ProductCompanyStageHype Score
DOR/ISLMerckPhase 2
35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
40
GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tabletShionogiPhase 1
29
GW810781ShionogiPhase 2
35
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABVCiplaApproved
43
Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mgEli LillyPhase 2
42
Epoetin alfaJohnson & JohnsonPre-clinical
26
LevofloxacinJohnson & JohnsonPhase 1
29
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；PlaceboJiangsu Hengrui MedicinePhase 1
29
ABBV-181 + PlaceboAbbViePhase 1
29
ABBV-382 + ABBV-382 + Placebo for ABBV-382AbbViePhase 1
29
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
43
lopinavir/ritonavir + lamivudineAbbViePre-clinical
26
Lopinavir/RitonavirAbbVieApproved
43
Budigalimab + Placebo + Budigalimab + PlaceboAbbViePhase 1
29
Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + BudigalimabAbbViePhase 2
27
CVC 150 mg + CVC 300 mgAbbViePhase 2
35
Rosuvastatin 10 mg. daily for 96 weeks + PlaceboAstraZenecaPhase 2
35
Indinavir sulfate + Lamivudine + ZidovudineMerckPhase 3
40
RosuvastatinAstraZenecaPhase 2
35